| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd5537af900106df1a2e4d63470098e3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 |
| filingDate |
2017-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f4bed309e6f08b1ad4c4266224125cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70ccc08846ec3fd840aa06d240caf65f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c70e6f92f29f0dc2d1a1a3d2a048e6c |
| publicationDate |
2018-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
PH-12017502086-A1 |
| titleOfInvention |
Cancer treatments |
| abstract |
The invention provides NUC-1031 (gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate), a ProTide derivative of gemcitabine,for use in targeting cancer stem cells. This targeting of cancer stem cells may be employed in the prevention or treatment of cancer. The invention also provides NUC-1031 for use in treatment of relapsed or refractorycancer in a human patient. Without wishing to be bound by any hypothesis, it is believed that the ability of NUC-1031 to target cancer stem cells contributes to its utility in the treatment of relapsed or refractory cancers. |
| priorityDate |
2015-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |